These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 17388216)

  • 1. Imiquimod in the treatment of alopecia universalis.
    Letada PR; Sparling JD; Norwood C
    Cutis; 2007 Feb; 79(2):138-40. PubMed ID: 17388216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463.
    Imbertson LM; Beaurline JM; Couture AM; Gibson SJ; Smith RM; Miller RL; Reiter MJ; Wagner TL; Tomai MA
    J Invest Dermatol; 1998 May; 110(5):734-9. PubMed ID: 9579537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod.
    Wagner TL; Ahonen CL; Couture AM; Gibson SJ; Miller RL; Smith RM; Reiter MJ; Vasilakos JP; Tomai MA
    Cell Immunol; 1999 Jan; 191(1):10-9. PubMed ID: 9918682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The effects of imiquimod on an animal model of asthma].
    Yin KS; Jin SX; Bian T; Wu QZ; Wang X; Yao X
    Zhonghua Jie He He Hu Xi Za Zhi; 2007 Jul; 30(7):509-17. PubMed ID: 17961405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ineffectiveness of imiquimod therapy for Alopecia Totalis/Universalis.
    D'Ovidio R; Claudatus J; Di Prima T
    J Eur Acad Dermatol Venereol; 2002 Jul; 16(4):416-7. PubMed ID: 12224709
    [No Abstract]   [Full Text] [Related]  

  • 6. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment.
    Urosevic M; Dummer R; Conrad C; Beyeler M; Laine E; Burg G; Gilliet M
    J Natl Cancer Inst; 2005 Aug; 97(15):1143-53. PubMed ID: 16077073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis.
    Majewski S; Marczak M; Mlynarczyk B; Benninghoff B; Jablonska S
    Int J Dermatol; 2005 Jan; 44(1):14-9. PubMed ID: 15663652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible advantage of imiquimod and diphenylcyclopropenone combined treatment versus diphenylcyclopropenone alone: An observational study of nonresponder patients with alopecia areata.
    Wasyłyszyn T; Borowska K
    Australas J Dermatol; 2017 Aug; 58(3):219-223. PubMed ID: 27087586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of cytokines in cynomolgus monkeys by the immune response modifiers, imiquimod, S-27609 and S-28463.
    Wagner TL; Horton VL; Carlson GL; Myhre PE; Gibson SJ; Imbertson LM; Tomai MA
    Cytokine; 1997 Nov; 9(11):837-45. PubMed ID: 9367544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imiquimod in clinical practice.
    Edwards L
    Australas J Dermatol; 1998 Nov; 39 Suppl 1():S14-6. PubMed ID: 9842096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulatory and pharmacologic properties of imiquimod.
    Sauder DN
    J Am Acad Dermatol; 2000 Jul; 43(1 Pt 2):S6-11. PubMed ID: 10861101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune response modification: imiquimod.
    Tyring S
    Australas J Dermatol; 1998 Nov; 39 Suppl 1():S11-3. PubMed ID: 9842095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod.
    Wolf IH; Cerroni L; Kodama K; Kerl H
    Arch Dermatol; 2005 Apr; 141(4):510-4. PubMed ID: 15837872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A preliminary study of imiquimod treatment in variants of basal cell carcinoma.
    McCutcheon B; White K; Kotwall C; Germolic D; Rebolloso Y; Hamann MS; Stiles A
    Am Surg; 2005 Aug; 71(8):662-5. PubMed ID: 16217949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod.
    Wenzel J; Uerlich M; Haller O; Bieber T; Tueting T
    J Cutan Pathol; 2005 Apr; 32(4):257-62. PubMed ID: 15769273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical imiquimod treatment prevents UV-light induced loss of contact hypersensitivity and immune tolerance.
    Thatcher TH; Luzina I; Fishelevich R; Tomai MA; Miller RL; Gaspari AA
    J Invest Dermatol; 2006 Apr; 126(4):821-31. PubMed ID: 16439962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum T helper 1 cytokine levels are greater in patients with alopecia areata regardless of severity or atopy.
    Barahmani N; Lopez A; Babu D; Hernandez M; Donley SE; Duvic M
    Clin Exp Dermatol; 2010 Jun; 35(4):409-16. PubMed ID: 19874320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine induction and modifying the immune response to human papilloma virus with imiquimod.
    Slade HB
    Eur J Dermatol; 1998; 8(7 Suppl):13-6; discussion 20-2. PubMed ID: 10387958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel dermatologic uses of the immune response modifier imiquimod 5% cream.
    Berman B; Poochareon VN; Villa AM
    Skin Therapy Lett; 2002 Nov; 7(9):1-6. PubMed ID: 12548325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and potential uses of imiquimod.
    Chang YC; Madkan V; Cook-Norris R; Sra K; Tyring S
    South Med J; 2005 Sep; 98(9):914-20. PubMed ID: 16217984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.